Literature DB >> 20637821

Agomelatine in the treatment of social anxiety disorder.

José Alexandre S Crippa, Jaime E C Hallak, Antonio Waldo Zuardi, Marcos Hortes N Chagas, João Quevedo, Antonio E Nardi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20637821     DOI： 10.1016/j.pnpbp.2010.07.007

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN： 0278-5846            Impact factor:   5.067


× No keyword cloud information.
  4 in total

1.  Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study.

Authors:  Michele Fornaro; Michael J McCarthy; Domenico De Berardis; Concetta De Pasquale; Massimo Tabaton; Matteo Martino; Salvatore Colicchio; Carlo Ignazio Cattaneo; Emanuela D'Angelo; Pantaleo Fornaro
Journal:  Neuropsychiatr Dis Treat       Date:  2013-02-15       Impact factor: 2.570

2.  Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series.

Authors:  Michele Fornaro
Journal:  Ann Gen Psychiatry       Date:  2011-02-28       Impact factor: 3.455

Review 3.  Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.

Authors:  Domenico De Berardis; Michele Fornaro; Nicola Serroni; Daniela Campanella; Gabriella Rapini; Luigi Olivieri; Venkataramanujam Srinivasan; Felice Iasevoli; Carmine Tomasetti; Andrea De Bartolomeis; Alessandro Valchera; Giampaolo Perna; Monica Mazza; Marco Di Nicola; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Int J Mol Sci       Date:  2015-01-05       Impact factor: 5.923

Review 4.  Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.

Authors:  Josiel Mileno Mack; Marissa Giovanna Schamne; Tuane Bazanella Sampaio; Renata Aparecida Nedel Pértile; Pedro Augusto Carlos Magno Fernandes; Regina P Markus; Rui Daniel Prediger
Journal:  Oxid Med Cell Longev       Date:  2016-10-18       Impact factor: 6.543
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.